



Annual IMPACT Report

2025



Thank you *for advocating*

Millions of people worldwide rely on insulin to survive, yet only about half of those who need it can reliably access or afford it. With the right medicines, care, and supplies, diabetes can be managed, but most people living with diabetes are in low- and middle-income countries, where options are limited. For the 9.5 million people living with type 1 diabetes, even a few hours without insulin can be fatal.

In a world where profit and power are too often prioritized over people's lives, finding hope can be difficult. Since our founding in 2013, T1International has grown into a movement of nearly a quarter million people demanding affordable insulin, equitable care, and an end to systems that treat health as a commodity. In 2025, we released our new Long-Term Strategic Plan, reflecting what we have learned: lasting change requires patient power, political courage, and sustained, independent advocacy.

Our patient-led, grassroots community has repeatedly shown that real solutions do not come from the top down. Change happens when people equipped with the training, tools, and connections stand up for their rights locally. This Impact Report highlights just some of the successes our community won in 2025, made possible by our Chapters, Partners, funders, donors, Team, and Trustees.

With love and gratitude,



Shaina Kasper

Executive Director of T1International



Photo Caption: US-based T1International Team members at the January action in Washington, D.C.

Our **Approach + Values**



T1International is a non-profit led by people with and impacted by diabetes, for people with diabetes, fighting for global healthcare equity.

Our Vision

We believe in a world where everyone with diabetes, no matter where they live, has everything they need to survive and achieve their dreams.


Our Mission

We support local communities by giving them the training, tools, community and networks they need to stand up for their rights so that access to insulin and diabetes supplies becomes a reality for all.

Our Values

The values of Patient-led, Independence, Transparency, Inclusivity, Boldness, and Hope serve to inspire us and hold us accountable alongside our action plans.

Our Network



Our Year in Numbers

3

insulins added to the World Health Organization's Essential Medicines List

23

World Diabetes Day events held in 12 countries

85

countries represented by more than 4,000 advocates taking action

600

advocates joined our call urging Novo Nordisk's new CEO to lower the price of insulin

1500+

signatures collected by the Egypt #insulin4all Chapter for a petition to Abbott, who manufacture Continuous Glucose Monitors (CGMs), urging them to address high costs in the Middle East and North Africa (MENA) region

5

presentations of our Out-of-Pocket Expenses Survey Report at conferences

13

entities convened in 6 US states and 3 countries to take action on public pharma

27

Advocates graduated from 2 New Advocate Speakers Bureau cohorts

75

people joined an #insulin4all Chapter throughout the year

100

lobby meetings held with members of the US Congress on patent reform, in addition to 3,500 letters sent



Photo Caption: Members of T1International's Partner group Network of Persons Living with Diabetes in Nigeria

How We **Make Change**

Run targeted and strategic advocacy campaigns

In 2025, we ran mobilizations for patent reform, public pharma, and to add rapid-acting insulins to the World Health Organization's Essential Medicines List. Over 30 public comments and thousands of petition signatures from 50+ countries were submitted in support of our successful Essential Medicines List campaign.

Build strong connections and collaborations

We worked with a wide range of partners and championed community-led research with the release of our fifth Out-of-Pocket Expenses and Rationing Survey Report, showing that one third of people living with diabetes rationed insulin in the past year.

Empower strong local groups

We welcomed three Advocacy Partners (two in the Democratic Republic of Congo, and one in Nigeria) and launched two #insulin4all Chapters, in Egypt and Vermont, USA, advancing our commitment to grassroots, locally driven advocacy.

Promote leadership among those most impacted

People directly impacted by the insulin crisis lead our work, grounding us in our ethical patient engagement principles. In 2025, advocates brought their stories to governments worldwide, the United Nations, and the World Health Organization, ensuring patients were heard at every level of global diabetes policy.



Photo Caption: Members of the Ohio #insulin4all Chapter in the United States complete an advocacy training

Our Stories



A Major Win for Global Insulin Access

In 2025, T1International achieved a hard-fought victory: the successful addition of rapid-acting insulin analogues to the World Health Organization (WHO) Essential Medicines List. This milestone came after other experts and academics declined to lead on submitting the application, which led to T1International drafting and submitting the application ourselves. We faced opposition from WHO staff, and mixed expert reviews.

Our advocacy actions included the delivery of public comments from our global community and a petition to the WHO headquarters in Geneva, Switzerland. Our application was ultimately approved after our first submission (whereas long-acting insulin analogues required three attempts!).

Adding these insulins to the Essential Medicines List is a critical step toward ending the double standard in diabetes care between the Global North and Global South, especially as human insulin pens have been discontinued globally. Currently, 137 countries follow the list for their national medicines lists, which means more countries will recognize rapid-acting insulins as essential and not a luxury.

I would like to commend T1International and the support networks who have worked so hard to get this done. After working in the field of type one diabetes for more than 10 years this is a major blessing!

**- Dr. Nana Ama,
Diabetes Youth
Care Ghana**

Photo Caption: T1International's Global Advocacy Manager delivers our petition to the WHO in Geneva

Our Stories



Being part of the patent mobilization was such a powerful experience. It was the first time I shared my story with policymakers and demanded change. I found the courage to speak out, to amplify other people's stories, and to fight for reform. Being part of T1's vital work makes me proud.

**- Courtney, Vermont
#insulin4all Chapter
Leader**

Challenging Patent Abuses to Lower Prices

Patents are intended to encourage innovation, but in the United States they have long been abused to block competition and keep insulin prices high. T1International prioritizes patent reform as a critical pathway to lower prices, increase competition, and enable public pharmaceutical production.

In February, T1International advocates took action in Washington, D.C. During the opening days of Congress, two dozen members of our Federal Working Group, Fight for Five Working Group, Families United for Affordable Insulin, and staff convened for a multi-day retreat, training, and advocacy push. Together, we organized a direct action and held in-person lobby meetings with Members of Congress and staff, building key relationships despite a crowded political moment.

We sustained this momentum through a national patent mobilization in the summer, engaging advocates across the United States to oppose harmful proposals and advance meaningful reforms. Advocates held dozens of lobby meetings, published op-eds, and sent constituent letters to Congress. While reform is still underway, we have built power, skills, and visibility for the fights ahead.

Photo Caption: #insulin4all Advocates lead a creative direct action outside the United States Capitol

Our Stories



A Global Call for Access and Affordability

In 2014, the Pendsey Trust and T1International launched the #insulin4all campaign in the lead-up to World Diabetes Day; although it began in 1991, the true spirit of the day (to highlight barriers and solutions for scaling up access to diabetes medicines, education, and care) had been lost over the years.

For World Diabetes Day 2025, #insulin4all advocates around the world took action to demand accessible and affordable life-sustaining diabetes medicines, organizing actions around the world. Volunteer leaders amplified these demands through media engagement, with press coverage across six countries. This global mobilization was supported by a dedicated training series that built advocates' skills and confidence in event planning, recruitment, messaging, and engaging the media.

In addition, advocates shared powerful personal stories and calls to action during a World Diabetes Day webinar. Together, these efforts strengthened global solidarity, expanded public visibility, and built lasting capacity for continued advocacy for insulin access and affordability worldwide.

T1International amplifies voices from every part of the world, especially from communities like Nigeria, where access is still a daily struggle. They ensure that the lived experience of people in low-income or middle-income countries is not just “included”, but centered.

**- Nkiruka,
T1International
Trustee**

Our Stories



T1International is the Johnny Appleseed of the access-to-medicines space, in the way they build the movement and help it grow. They are the most engaged, involved, and powerful of the patient advocacy groups.

- Chris, New York University School of Law, USA

Building Momentum for Public Pharma

At T1International, we know that insulin access cannot depend on corporate monopolies. Just three companies control the global insulin supply, driving prices far beyond what it costs to produce high-quality insulin. While sustainable insulin pens can be made for under \$10, people in our community reported paying over \$130 on average. These companies also decide when to discontinue products, leaving patients at risk, as seen when Novo Nordisk announced it would phase out human insulin pens and Levemir.

We are advancing a different solution: governments manufacturing, procuring, and distributing essential medicines. Momentum is growing. In Brazil, the government announced plans to domestically produce human insulin and glargine. In the United States, more states joined the public pharmacy consortium ArrayRx, and California advanced its CalRx insulin program to offer transparently priced, low-cost insulin without rebates.

Our United States #insulin4all Chapters also laid the groundwork to win state policy. Through strategy retreats, leadership development, and community education, advocates built the power needed to advance Public Pharma in 2026 and beyond.

Photo Caption: T1International staff, Chapter members, and partners speak on a Public Pharma panel in New York

Our **Finances**

Our finances relate to funds raised, managed and spent through T1International USA, a tax-exempt organisation (EIN: 84-2544817) under section 501(c)(3) of the United States Internal Revenue Code.

Expenditure

\$338,176

Direct Programs

\$110,777

Core Staff and
Consultant Costs

\$53,280

Operational Costs



Income

\$95,208

Grants

\$157,010

Individual
Donations

\$32,743

Corporates &
Community

Photo Caption: #insulin4all advocates take action in Washington, D.C. for patent reform

A huge thanks to our donors for their *support.*

Our advocacy is resource-intensive and deliberately independent: we do not accept funding from pharmaceutical companies. This commitment ensures our ability to hold powerful actors accountable and center the lived experiences of people directly impacted by insulin inaccessibility. Despite financial uncertainty across the field, our community's support has enabled us to remain focused, resilient, and effective.

Acknowledgements

Anonymous
Arnold Ventures
Jockey Hollow Foundation
McPike-Zima Foundation
NYU Engelberg Center on Innovation
Law & Policy
Red Sox Foundation

Our Global G1vers provide regular support that empowers our team in a sustainable, ongoing way.



Our Partners

At T1International, we believe that by working together we can make a bigger impact in the lives of people living with diabetes than if we were only working as individual organizations. We work with partners on projects or programs, and we act with mutual recognition and allyship on our collective goals.

- Diabetes Advocacy and Support (Nigeria)
- Diabet Centro (Guatemala)
- Diabetes Consciousness for Community - DiCoCo (Tanzania)
- Diabetes Fighters Trust (India)
- Diabetes LATAM (Panama)
- Diabète et Méchant (France)
- Gavin Gill Foundation (USA)
- Help Madina (Sierra Leone)
- Kivu Diabetes Center (Democratic Republic of Congo)
- Meethi Zindagi (Pakistan)
- Network of Persons Living with Diabetes (Nigeria)
- New York University Science, Health, and Information Clinic (USA)
- Santé Diabète (Burkina Faso, Comoros, France, & Mali)
- Universities Allied for Essential Medicines (USA)
- We Care Sierra Leone (Sierra Leone)

I am proud to be an Advocacy Partner with T1International. Our work is bearing fruit, and I remain confident that we will reach a stage where no child should ever die from diabetes in the Democratic Republic of Congo.

**- Dr. Albert, Kivu
Diabetes Center**



Photo Caption: #insulin4all Advocates at Kivu Diabetes Center, a T1International Partner, in DRC

Your strength, support,
encouragement and fight drives
me to do more. The skills that I
am acquiring are remarkable.

The world is a better place
because of T1International.
The achievements are real!
I am so proud to be part of
fundamental change.

- Janice, South Africa
#insulin4all Chapter Leader